Evidence map›Paper›PMID 28977838›Full record

ArticleOncotarget2017

Hepatitis B virus X protein-induced upregulation of CAT-1 stimulates proliferation and inhibits apoptosis in hepatocellular carcinoma cells.

Rongjuan Dai, Feng Peng, Xinqiang Xiao, Xing Gong, Yongfang Jiang, Min Zhang, Yi Tian, Yun Xu, Jing Ma, Mingming Li and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rongjuan DaiDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Feng PengDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Xinqiang XiaoDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Xing GongDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Yongfang JiangDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Min ZhangDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Yi TianDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Yun XuDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Jing MaDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Mingming LiDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Yue LuoDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.
Guozhong GongDepartment of Infectious Diseases, Institute of Hepatology Central South University, Second Xiangya Hospital, Central South University, Changsha, Hunan 410011, PR China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The HBx protein of hepatitis B virus (HBV) is widely recognized to be a critical oncoprotein contributing to the development of HBV-related hepatocellular carcinoma (HCC). In addition, cationic amino acid transporter 1 (CAT-1) gene is a target of miR-122. In this study, we found that CAT-1 protein levels were higher in HBV-related HCC carcinomatous tissues than in para-cancerous tumor tissues, and that CAT-1 promoted HCC cell growth, proliferation, and metastasis. Moreover, HBx-induced decreases in Gld2 and miR-122 levels that contributed to the upregulation of CAT-1 in HCC. These results indicate that a Gld2/miR-122/CAT-1 pathway regulated by HBx likely participates in HBV-related hepatocellular carcinogenesis.

Indexed as

CAT-1Gld2HBxHCCmiR-122

Identifiers

PMID28977838
PMCPMC5617398

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.